Repligen's (RGEN) "Buy" Rating Reaffirmed at HC Wainwright

Repligen (NASDAQ:RGEN - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $180.00 target price on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 27.20% from the stock's previous close.

Several other research firms have also weighed in on RGEN. Royal Bank of Canada lowered their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a research note on Tuesday, April 29th. Evercore ISI assumed coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Canaccord Genuity Group dropped their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Finally, TD Cowen initiated coverage on shares of Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $141.51 on Monday. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -277.47, a PEG ratio of 4.54 and a beta of 1.27. Repligen has a one year low of $102.97 and a one year high of $182.52. The business has a fifty day simple moving average of $137.82 and a 200 day simple moving average of $145.89. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same period last year, the firm earned $0.28 EPS. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. Sell-side analysts expect that Repligen will post 1.72 EPS for the current year.

Insider Activity at Repligen

In other news, Director Margaret Pax bought 250 shares of the stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

Large investors have recently made changes to their positions in the company. UMB Bank n.a. raised its holdings in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in shares of Repligen during the fourth quarter worth approximately $216,000. Van ECK Associates Corp raised its stake in shares of Repligen by 7.8% during the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after buying an additional 3,066 shares during the last quarter. Stephens Investment Management Group LLC lifted its holdings in Repligen by 7.4% in the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock valued at $77,267,000 after buying an additional 37,057 shares during the period. Finally, Artemis Investment Management LLP boosted its stake in Repligen by 18.4% in the fourth quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company's stock valued at $22,143,000 after acquiring an additional 23,905 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.